MYCOBACTERIUM
TUBERCULOSIS BACTERIOLOGICALLY
CONFIRMED
NEW CASES & RESISTANCE RATES (1995-2012)
|
YEAR |
NEW CASES (TOTAL) No |
NEW CASES (GREEKS) No (%) |
NEW CASES (FOREIGN-BORN) No (%) |
RES INH [ANY] (GREEKS) No (%) |
RES INH [ANY] (FOREIGN-BORN) No (%) |
RES [ANY] (GREEKS) No (%) |
RES [ANY] (FOREIGN-BORN) No (%) |
MDR (GREEKS) No (%) |
MDR (FOREIGN-BORN) No (%) |
|
1995 |
320 |
280 (87.5) |
40 (12.5) |
16 (5.7) |
6 (17.5) |
6 (2.1) |
2 (5.7) |
3 (1.0) |
2 (5.7) |
|
1996 |
336 |
283 (84.2) |
53 (15.8) |
15 (5.3) |
9 (15.7) |
3 (1.0) |
2 (4.8) |
2 (0.7) |
2 (4.8) |
|
1997 |
344 |
294 (85.5) |
50 (14.5) |
22 (7.5) |
23 (50.4) |
7 (2.4) |
10 (21.3) |
6 (2.0) |
11 (24.5) |
|
1998 |
410 |
304 (74.1) |
106 (25.9) |
25 (8.2) |
14 (13.2) |
8 (2.6) |
7 (6.6) |
6 (2.0) |
7 (6.6) |
|
1999 |
545 |
452 (82.9) |
93 (17.1) |
34 (7.5) |
16 (17.2) |
23 (5.1) |
11 (11.8) |
22 (4.9) |
10 (10.8) |
|
2000 |
650 |
535 (82.3) |
115 (17.7) |
26 (4.9) |
9 (7.8) |
20 (3.7) |
3 (2.6) |
17 (3.2) |
3 (2.6) |
|
2001 |
628 |
491 (78.2) |
137 (21.8) |
38 (7.7) |
12 (8.8) |
10 (2.0) |
4 (2.9) |
10 (2.0) |
3 (2.2) |
|
2002 |
520 |
362 (69.6) |
158 (30.4) |
27 (7.5) |
13 (8.2) |
13 (3.6) |
11 (7.0) |
12 (3.3) |
8 (5.1) |
|
2003 |
540 |
387 (71.7) |
153 (28.3) |
42 (10.8) |
23 (15.0) |
20 (5.2) |
10 (6.5) |
15 (3.9) |
6 (3.9) |
|
2004 |
460 |
282 (61.3) |
178 (38.7) |
35 (12.4) |
20 (11.2) |
12 (4.3) |
7 (3.9) |
7 (2.5) |
7 (3.9) |
|
2005 |
497 |
319 (64.2) |
178 (35.8) |
20 (6.3) |
12 (6.7) |
13 (4.1) |
10 (5.6) |
9 (2.8) |
6 (3.4) |
|
2006 |
466 |
312 (67.0) |
154 (33.0) |
12 (3.8) |
10 (6.5) |
7 (2.2) |
12 (7.8) |
4 (1.3) |
9 (5.8) |
|
2007 |
454 |
262 (57.7) |
192 (42.3) |
9 (3.4) |
25 (13.0) |
4 (1.5) |
14 (7.3) |
1 (0.4) |
12 (6.3) |
|
2008 |
431 |
245 (56.8) |
186 (43.2) |
25 (10.2) |
15 (8.1) |
8 (3.2) |
6 (3.2) |
8 (3.2) |
5 (2.7) |
|
2009 |
441 |
201 (45.6) |
240οΏ½ (54.4) |
7 (3.4) |
19 (7.9) |
4 (1.9) |
12 (5.0) |
4 (1.9) |
11 (4.6) |
|
2010 |
461 |
154 (33.4) |
307 (66.6) |
8 (5.2) |
18 (5.9) |
3 (1.9) |
9 (2.9) |
3 (1.9) |
8
(2.6) |
|
2011 2012 |
444 422 |
174 (39.2) 197 (47%) |
270 (60.8) 225 (53%) |
8 (4.6) 20 (10.1) |
28 (10.4) 19 (8.4%) |
4 (2.3) 4 (2%) |
13 (4.8) 7 (3.1%) |
3 (1.7) 4 (2%) |
13 (4.8) 7
(3.1) |
|
Total |
8369 |
5534 (66) |
2835 (34) |
389 (7) |
291 (10) |
169 (3) |
150 (5.3) |
136 (2.5) |
130 (4.6) |
οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½ Data from
the Microbiology Department οΏ½ National Reference Laboratory for Mycobacteria,
MDR vs.XDR Mycobacterium tuberculosis among Native
Greeks and Foreign-born (2006-2012)
|
YEAR |
MTB NoοΏ½ (%) |
MDR No (%) |
XDR No (%) |
XDR/MDR (%) |
||||||||
|
|
TOTAL |
GREEKS |
IMMI-GRANTS |
TOTAL |
GREEKS |
IMMI-GRANTS |
TOTAL |
GREEKS |
IMMI-GRANTS |
TOTAL |
GREEKS |
IMMI-GRANTS |
|
2006 |
466 |
312 οΏ½(67) |
154 (33) |
13 (2.8) |
4 (1.3) |
9 (5.8) |
1 (0.2) |
1 (1.3) |
0 (0) |
9.1 |
25 |
0 |
|
2007 |
454 |
262 (57.7) |
192 (42.3) |
13 (2.86) |
1 (0.4) |
12 (6.3) |
0 (0) |
0 (0) |
0 (0) |
οΏ½22.5 |
0 |
0 |
|
2008 |
431 |
245 (56.8) |
186 (43.2) |
13 (3) |
8 (3.2) |
5 (2.7) |
4 (0.9) |
2 (0.8) |
2 (1.1) |
30.7 |
25 |
40 |
|
2009 |
441 |
201 (45.6) |
240 (54.4) |
15 (3.4) |
4 (1.9) |
11 (4.6) |
2 (0.5) |
2 (1) |
0 (0) |
13.3 |
50 |
0 |
|
2010 |
461 |
154 (33.4) |
307 (66.6) |
11 (2.4) |
3
(1.9) |
8
(2.6) |
5 (1.1) |
0 (0) |
5 (1.6) |
45.5 |
0 |
62.5 |
|
2011 |
444 |
174 (39.2) |
270 (60.8) |
16 (3.6) |
3 (1.7) |
13 (4.8) |
4 (0.9) |
0 (0) |
4 (1.5) |
25 |
0 |
30.7 |
|
2012 |
422 |
197 (47) |
225 (53) |
11 (2.6) |
4 (2) |
7
(3.1) |
1 (0.2) |
0 (0) |
1 (0.4) |
9 |
0 |
14.3 |
|
TOTAL (2006-2012) |
3119 |
1545 (50) |
1574 (50) |
92 |
27 (29) |
65 (71) |
17 |
5 (29) |
12 (71) |
18.5 |
18.5 |
18.5 |
οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½ Data from
the Microbiology Department οΏ½ National Reference Laboratory for Mycobacteria,
Bacteriologically confirmed
new tuberculosis cases among Native Greeks and Foreign-born (1995-2012)
οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½ Data from
the Microbiology Department οΏ½ National Reference Laboratory for Mycobacteria,
Any Resistance (%) to Isoniazid (INH), Rifampicin (
(1993-2012)
οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½ Data from
the Microbiology Department οΏ½ National Reference Laboratory for Mycobacteria,
Any Resistance (%) to Isoniazid (INH), Rifampicin (
(1993-2012)
οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½ Data from the Microbiology
Department οΏ½ National Reference Laboratory for Mycobacteria,
Resistance phenotypes against first-line anti-tuberculous
drugs (Greeks & Foreign-born)
(1995-2012)
|
YEAR |
1995 |
1996 |
1997 |
1998 |
1999 |
2000 |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
TOTAL |
|
SEN |
264 |
292 |
279 |
351 |
470 |
596 |
558 |
460 |
452 |
390 |
400 |
412 |
392 |
384 |
400 |
420 |
373 |
367 |
7284 |
|
SM |
26 |
9 |
18 |
15 |
15 |
16 |
18 |
12 |
14 |
10 |
23 |
22 |
23 |
11 |
13 |
20 |
16 |
5 |
286 |
|
INH |
7 |
9 |
13 |
10 |
6 |
8 |
17 |
11 |
16 |
26 |
8 |
1 |
5 |
6 |
5 |
2 |
10 |
14 |
174 |
|
SM+INH |
5 |
6 |
8 |
10 |
6 |
9 |
15 |
7 |
24 |
10 |
6 |
5 |
9 |
10 |
6 |
5 |
10 |
4 |
155 |
|
SM+INH+EMB+RIF |
3 |
2 |
11 |
2 |
8 |
2 |
4 |
6 |
9 |
7 |
6 |
6 |
12 |
2 |
4 |
2 |
|
5 |
91 |
|
INH+RIF |
|
|
1 |
2 |
4 |
7 |
3 |
9 |
7 |
2 |
1 |
3 |
|
3 |
|
1 |
|
3 |
46 |
|
SM+EMB+INH |
1 |
3 |
4 |
|
3 |
|
2 |
|
4 |
3 |
6 |
3 |
6 |
5 |
1 |
4 |
1 |
|
46 |
|
RIF |
3 |
1 |
|
3 |
1 |
|
1 |
4 |
6 |
3 |
5 |
3 |
2 |
|
1 |
1 |
1 |
|
35 |
|
INH+SM+RIF |
1 |
1 |
1 |
2 |
5 |
1 |
2 |
4 |
4 |
3 |
2 |
4 |
1 |
|
2 |
3 |
3 |
1 |
40 |
|
EMB |
2 |
9 |
2 |
|
3 |
|
1 |
3 |
1 |
1 |
1 |
5 |
|
|
|
1 |
|
|
29 |
|
PZA+SM+INH+EMB+ |
|
|
2 |
3 |
10 |
1 |
4 |
|
|
|
|
|
|
|
6 |
|
10 |
4 |
40 |
|
INH+EMB |
2 |
|
1 |
3 |
1 |
|
|
|
2 |
1 |
|
|
|
1 |
|
1 |
|
|
12 |
|
INH+EMB+RIF |
|
2 |
1 |
2 |
|
1 |
|
1 |
|
2 |
2 |
|
|
|
|
|
2 |
|
13 |
|
SM+PZA+INH+RIF |
|
|
1 |
1 |
3 |
3 |
1 |
|
|
|
|
|
|
1 |
|
1 |
|
1 |
12 |
|
PZA+INH+EMB+RIF |
1 |
|
|
1 |
1 |
|
1 |
|
|
|
|
|
|
4 |
2 |
|
|
|
10 |
|
SM+EMB |
1 |
1 |
|
1 |
|
2 |
|
|
|
|
2 |
|
1 |
|
|
|
|
|
8 |
|
SM+EMB+RIF |
|
|
|
2 |
1 |
|
|
|
1 |
|
3 |
|
1 |
|
|
|
|
|
8 |
|
SM+RIF |
|
|
|
1 |
|
1 |
|
|
|
1 |
1 |
|
2 |
1 |
|
|
1 |
1 |
9 |
|
PZA |
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
15 |
12 |
32 |
|
SM+PZA+INH |
1 |
|
|
1 |
|
|
1 |
|
|
|
|
|
|
2 |
|
|
|
|
5 |
|
PZA+INH+EMB |
|
1 |
|
|
1 |
|
|
3 |
|
|
|
|
|
|
|
|
|
|
5 |
|
SM+PZA+INH+EMB |
|
|
2 |
|
1 |
1 |
|
|
|
|
|
|
|
1 |
|
|
|
1 |
6 |
|
EMB+RIF |
|
|
|
|
|
|
|
|
|
1 |
1 |
2 |
|
|
|
|
|
|
4 |
|
SM+PZA |
2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
1 |
4 |
|
PZA+INH |
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
2 |
4 |
|
PZA+EMB |
|
|
|
|
1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
SM+PZA+EMB |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
|
|
1 |
|
PZA+INH+RIF |
|
|
|
|
|
1 |
|
|
|
|
|
|
|
|
|
|
|
1 |
2 |
|
SM+PZA+EMB+RIF |
|
|
|
|
|
1 |
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
PZA+RIF |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0 |
|
SM+PZA+RIF |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0 |
|
TOTAL |
320 |
336 |
344 |
410 |
545 |
650 |
628 |
520 |
540 |
460 |
467 |
466 |
454 |
431 |
441 |
461 |
444 |
422 |
8369 |
SM: streptomycin, INH: isoniazid,
οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½ Data from the
Microbiology Department οΏ½ National Reference Laboratory for Mycobacteria,
Resistance phenotypes against first-line anti-tuberculous
drugs (1995-2011)
οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½οΏ½ Data from the Microbiology
Department οΏ½ National Reference Laboratory for Mycobacteria,
οΏ½ 2013οΏ½οΏ½οΏ½ Last modified by D. Papaventsis:οΏ½ March 2013